NextCure Announces Pricing of Public Offering of Common Stock
November 14 2019 - 10:10PM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical
company committed to discovering and developing novel,
first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced the pricing of its public
offering of 4,077,192 shares of its common stock at a public
offering price of $36.75 per share. NextCure also granted the
underwriters a 30-day option to purchase up to an additional
611,578 shares of its common stock at the public offering price
less the underwriting discounts and commissions. All of the common
stock to be sold in the offering are being offered by NextCure.
Gross proceeds from the offering, before deducting underwriting
discounts and commissions and estimated offering expenses, will be
approximately $150 million, excluding any exercise of the
underwriters’ option to purchase additional shares. The offering is
expected to close on or about November 19, 2019, subject to the
satisfaction of customary closing conditions.
Morgan Stanley, BofA Securities and Piper Jaffray & Co. are
acting as joint book-running managers for the offering. Needham
& Company and BTIG are acting as co-managers for the
offering.
A registration statement relating to the shares being sold in
the offering was declared effective by the Securities and Exchange
Commission (SEC) on November 14, 2019. The offering is being made
only by means of a prospectus. Copies of the final prospectus, when
available, may be obtained by visiting EDGAR on the SEC’s website
at www.sec.gov or from: Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, New
York 10014; BofA Securities, NC1-004-03-43, 200 North College
Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn:
Prospectus Department, or by email at
dg.prospectus_requests@baml.com; Piper Jaffray & Co., 800
Nicollet Mall, J12S03, Minneapolis, Minnesota, 55402, Attention:
Prospectus Department, by telephone at (800) 747-3924 or by email
at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About NextCure, Inc.NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Media Inquiries
Shai Biran, Ph.D.
MacDougall
(781) 235-3060
sbiran@macbiocom.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Sep 2023 to Sep 2024